T13571 |
JAK-IN-10
|
916741-98-5
|
98.88%
|
|
JAK-IN-10 is a JAK inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.
|
T22142 |
RO8191
|
691868-88-9
|
98.85%
|
|
RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.
|
T10009 |
JAK3-IN-7
|
1263774-57-7
|
98.81%
|
|
JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after organ...
|
T6122 |
CEP-33779
|
1257704-57-6
|
98.81%
|
|
CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
|
T20742 |
TG-89
|
936091-56-4
|
98.8%
|
|
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
|
T11710 |
JAK-IN-5
|
2096999-92-5
|
98.78%
|
|
JAK-IN-5 is a JAK inhibitor.
|
T1849 |
Momelotinib
|
1056634-68-4
|
98.75%
|
|
Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 comp...
|
T6294 |
NVP-BSK805 2HCl (1092499-93-8(free base))
|
T6294
|
98.75%
|
|
NVP-BSK805 2HCl (1092499-93-8(free base)) (BSK 805)(IC50=0.5 nM), a specific and effective ATP-competitive JAK2 inhibitor, is more than 20-fold specificity over ...
|
T67894 |
Butyzamide
|
1110767-45-7
|
98.71%
|
|
Butyzamide is an effective and oral Mpl activator. It is a novel non-peptide-based molecule with antagonistic effects on thrombopoietin (TPO) receptors, which pr...
|
T3080 |
Pyridone 6
|
457081-03-7
|
98.7%
|
|
Pyridone 6 (JAK Inhibitor)(CMP 6) is a potent and selective inhibitor of JAK1 (IC50=15 nM, murine JAK1), JAK2 (IC50=1 nM), JAK3 (Ki=5 nM), and Tyk2 (IC50=1 nM); ...
|
T2853 |
Curcumol
|
4871-97-0
|
98.57%
|
|
Curcumol ((-)-Curcumol), a pure monomer isolated extracted from Rhizoma Curcumaeis, has antitumor activities.
|
T3069 |
AZD-1480
|
935666-88-9
|
98.55%
|
|
AZD1480 is a novel ATP-competitive JAK2 inhibitor (IC50: 0.26 nM), selectivity act against Tyk2 and JAK3, and to a smaller extent against JAK1. AZD1480 has been ...
|
T4657L |
WHI-P97 HCl 211555-05-4(free base)
|
T4657L
|
98.55%
|
|
WHI-P97 HCl is a potent and selective JAK-3 inhibitor. WHI-P97 had an estimated Ki value of 0.09 microM from modeling studies and a measured IC50 value of 2.5 mi...
|
T14687 |
Deucravacitinib
|
1609392-27-9
|
98.52%
|
|
Deucravacitinib (BMS-986165) inhibits IL-12/23 and type I IFN pathways[1][2]. BMS-986165 is a highly selective, orally bioavailable allosteric TYK2 inhibitor for...
|
T6309 |
AZ960
|
905586-69-8
|
98.51%
|
|
AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).
|
T3398 |
Icaritin
|
118525-40-9
|
98.50%
|
|
Icaritin (Anhydroicaritin) has hormone regulation activity and cardiovascular function improvement activity. Icaritin has anticancer activity, can induce S phase...
|
T4227 |
SB1317 hydrochloride (1204918-72-8(free base))
|
T4227
|
98.39%
|
|
SB1317 hydrochloride (1204918-72-8(free base)) (TG-02 hydrochloride) is an effective inhibitor of CDK2/JAK2/FLT3 (IC50: 13/73/56 nM).
|
T35899 |
JAK1-IN-8
|
1973485-18-5
|
98.36%
|
|
JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).
|
TQ0196 |
Cucurbitacin I
|
2222-07-3
|
98.2%
|
|
Cucurbitacin I (JSI-124), a natural compound, is a selective inhibitor of JAK2/STAT3 with anti-cancer activity.
|
T2012 |
Oclacitinib
|
1208319-26-9
|
98.12%
|
|
Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000 n...
|